15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Tscan Therapeutics Inc, 1 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $1.00 to $7.00 (about 7.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.67 sits 1260% above the current $0.34. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.73 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy125%
Hold375%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Tscan Therapeutics Inc.
As of Sep, 1 of 4 firms rate TCRX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TCRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.23 – $-0.13 · 4 analysts · +4% YoY
Next period, 4 analysts expect Tscan Therapeutics Inc to earn $-0.19 a share (range $-0.23 – $-0.13), versus $-0.18 a year earlier. Full-year consensus is $-0.85, growing to $-0.73 the year after.
REVENUE · NEXT QUARTER
$1.1M
Range $0 – $2.5M · 4 analysts · -59% YoY
Revenue is expected to reach $1.1M (range $0 – $2.5M), -59.1% year-over-year. Full-year consensus is $5.5M, rising to $4.7M next year.
Top analysts covering Tscan Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TCRX.
#1
David Nierengarten
Wedbush · Rank #66
Hold
$1.00+191.4% to target
Overall win rate
42%
+ Follow
#2
Andres Y. Maldonado
HC Wainwright & Co. · Rank #227
Buy
$7.00+1939.6% to target
Overall win rate
39%
+ Follow
#3
Gil Blum
Needham · Rank #340
Hold
No targeton TCRX
Overall win rate
26%
+ Follow
#4
MS
Maxwell Skor
Morgan Stanley
Hold
No targeton TCRX
Coverage
—
+ Follow
#5
Tara Bancroft
TD Cowen
Buy
No targeton TCRX
Coverage
—
+ Follow
TCRX stock forecast FAQ
What is TCRX's average 12-month price target?+
The 2 analysts with a live target average $4.67 for Tscan Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $1.00 low.
Is TCRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 1 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TCRX?+
The Street-high target is $7.00 (HC Wainwright & Co.), and the Street-low is $1.00 (Wedbush). The average of all 2 active targets is $4.67.
How many Wall Street analysts cover TCRX?+
4 analysts have an active rating on Tscan Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering TCRX?+
Among analysts who currently cover TCRX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #66). Their current call is Hold with a $1.00 target.
What is Tscan Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.23 – $-0.13) across 4 analysts. Full-year EPS is projected at $-0.85, rising to $-0.73 the following year.
How much revenue is Tscan Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.1M (range $0 – $2.5M). Full-year revenue is projected at $5.5M, growing to $4.7M next year.
Have analysts been upgrading or downgrading TCRX lately?+
As of Sep, 1 of 4 firms rate TCRX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
